---
title: ESTEVE CDMO vs Merck KGaA
slug_a: esteve-cdmo
slug_b: merck-kgaa
site: cdmo
review_signal_gate: closed
canonical_path: /compare/esteve-cdmo/merck-kgaa
---

# ESTEVE CDMO vs Merck KGaA

Side-by-side profile data from each company listing on this directory.

## ESTEVE CDMO

- Profile: [/companies/esteve-cdmo](/companies/esteve-cdmo)

ESTEVE CDMO — ESTEVE CDMO is adding manufacturing capacity in the USA and China, including a $33 million expansion at its Morton Grove, Illinois site. Its China investment adds three manufacturing workshops with 250 m³ of total reaction volume, and its US assets add early development capabilities.

Services: 0. Modalities: 0. Indications: 0. Locations: 2. Certifications: 0. The strongest documented coverage currently appears in locations (2).

### Services

- Data not yet provided.

### Modalities

- Data not yet provided.

### Development capabilities

- Data not yet provided.

### Manufacturing capabilities

- Data not yet provided.

## Merck KGaA

- Profile: [/companies/merck-kgaa](/companies/merck-kgaa)

Merck KGaA — Recent coverage reports that Merck KGaA plans to sell its life science CDMO business to Lonza. The same coverage describes a new €300 million bioprocessing center in Daejeon, South Korea.

Services: 0. Modalities: 0. Indications: 0. Locations: 1. Certifications: 0. The strongest documented coverage currently appears in locations (1).

### Services

- Data not yet provided.

### Modalities

- Data not yet provided.

### Development capabilities

- Data not yet provided.

### Manufacturing capabilities

- Data not yet provided.